A5001936233- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Eosinophilic Disorders and Syndromes
- Immune cells in cancer
- T-cell and B-cell Immunology
- Lymphoma Diagnosis and Treatment
- Nerve injury and regeneration
- Cancer Immunotherapy and Biomarkers
- Axon Guidance and Neuronal Signaling
- Chronic Lymphocytic Leukemia Research
- Neurogenesis and neuroplasticity mechanisms
- Acute Myeloid Leukemia Research
- Cancer Cells and Metastasis
- Pancreatic and Hepatic Oncology Research
Copenhagen University Hospital
2022-2024
Herlev Hospital
2022-2023
Aarhus University
2022
Danish Diabetes Academy
2022
The majority of JAK2 V617F -negative myeloproliferative neoplasms (MPNs) have disease-initiating frameshift mutations in calreticulin ( CALR ), resulting a common carboxyl-terminal mutant fragment (CALR MUT representing an attractive source neoantigens for cancer vaccines. However, studies shown that -specific T cells are rare patients with MPN unknown reasons. We examined class I major histocompatibility complex (MHC-I) allele frequencies from two independent cohorts. observed MHC-I alleles...
Circulating transforming growth factor-β (TGF-β)-specific T cells that recognize TGF-β-expressing immune regulatory have been described in patients with cancer. TGF-β-derived peptide vaccination modulates the tumor microenvironment and has shown clinical effects animal models of pancreatic cancer (PC). are especially elevated PC may prevent response to checkpoint inhibitors (ICIs). Thus, present study we investigated significance TGF-β-specific T-cell immunity treated ICI combined...
Arginase-1 (Arg1) is expressed by regulatory myeloid cells in the tumor microenvironment (TME), where they play a pro-tumorigenic and T-cell suppressive role. Arg1-specific CD4+ CD8+ memory T have been observed both healthy individuals cancer patients. However, while function of anti-regulatory has characterized, our knowledge only scarce. In current study, we describe immune-modulatory capabilities cells. We generated cell clones to target Arg1-expressing Our results demonstrate that these...
Introduction Arginase-1 (ARG1) and Programed death ligand-1 (PD-L1) play a vital role in immunosuppression myeloproliferative neoplasms (MPNs) directly inhibit T-cell activation proliferation. We previously identified spontaneous responses towards PD-L1 ARG1 derived peptide epitopes patients with MPNs. In the present First-in-Man study we tested dual vaccinations of ARG1- PD-L1-derived peptides, combined Montanide ISA-51 as adjuvant, Janus Kinase 2 (JAK2) V617F-mutated MPN. Methods Safety...
Peripheral nerve regeneration relies on the ability of Schwann cells to support regrowth damaged axons. re-differentiate when reestablishing contact with sprouting axons, large fibers becoming remyelinated and small nociceptive ensheathed collected into Remak bundles. We have previously described how receptor sortilin facilitates neurotrophin signaling in peripheral neurons via regulated trafficking Trk receptors. This study aims characterize effects deletion following sciatic crush injury....
High expression of the metabolic enzyme arginase-2 (ARG2) by cancer cells, regulatory immune or cells tumor stroma can reduce availability arginine (L-Arg) in microenvironment (TME). Depletion L-Arg has detrimental consequences for T and leads to T-cell dysfunction suppression anticancer responses. Previous work from our group demonstrated presence proinflammatory ARG2-specific CD4 that inhibited growth murine models on activation with ARG2-derived peptides. In this study, we investigated...
Chronic lymphocytic leukemia (CLL) patients with unmutated immunoglobulin heavy chain (IgHV) are at risk of early disease progression compared to mutated IgHV. As a preventive strategy, we treated 19 previously untreated CLL IgHV in phase 1/2 trial (clinicaltrials.gov, NCT03939234) exploring the efficacy and toxicity therapeutic cancer vaccine containing peptides derived from programmed death ligand 1 (PD-L1) 2 (PD-L2), hoping restore immunological control disease. According International...
Background Therapeutic cancer vaccination against mutant calreticulin ( CALR ) in patients with -mutant mut) myeloproliferative neoplasms (MPN) induces strong T-cell responses yet fails to demonstrate clinical activity. Infiltration of tumor specific T cells into the microenvironment is needed attain a response therapeutic vaccination. Aim Determine if CALRmut isolated from vaccinated enrich bone marrow upon completion and explore possible explanations for lack enrichment. Methods four ten...
<h3>Background</h3> Chronic myeloproliferative neoplasms (MPN) are a group of diseases that characterized by the hyperproliferation mutated hematopoietic stem cells (HSCs) in bone marrow. Clinically, they can progress to myelofibrosis and acute myeloid leukemia. Megakaryocytic hyperplasia is known drive fibrotic progression through secretion fibrosis-promoting factors such as transforming growth factor beta (TGFβ). Previous work from our has demonstrated existence proinflammatory...